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Breast cancer is projected to be the most common cancer in women in 2020 in the United States. 
Despite high remission rates, treatment side-effects remain an issue, hence the interest in novel 
approaches such as immunotherapies which aim to utilise patients’ immune systems to target 
cancer cells. This review summarises the basics of breast cancer including staging and treatment 
options, followed by a discussion on immunotherapy, including immune checkpoint blockade. After 
this, examples of the role of omics-type data and computational biology/bioinformatics in breast 
cancer are explored. Ultimately, there are several promising areas to investigate such as the 
prediction of neoantigens and the use of multi-omics data to direct research, with noted appropriate 
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Introduction to Breast Cancer 
 
In the past quarter of a century the prevalence of breast cancer has increased by approximately 
40%, and it is projected to be the most common cancer in women in 2020 in the United States [1-3]. 
Breast cancer can be classified based on , the grade of the cancer cells, the stage of the tumour, and 
specific gene/protein markers & molecular pathology, with particular emphasis on the latter in 
recent years [4, 5], with. most Most breast cancers or associated benign neoplasms beginning begin 
in the ducts or lobules of the breast [6], with n. Non-invasive breast neoplasms can be classified as 
lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS) [7]. LCIS is seen as a risk factor for 
breast cancer development, whilst the malignant transformation for DCIS may take longer. 
Development of LCIS or DCIS into invasive cancers (invasive lobular carcinoma and 
invasive/infiltrating carcinoma respectively) is characterised by overall lack of architecture and 
haphazard tissue organisation [7]. 
 
Risk factors for breast cancer include age, personal and family history of breast cancer, reproductive 
milestones that increase a woman’s oestrogen exposure, exogenous hormone use, and genetic 
factors such as BRCA1/BRCA2 mutations [7]. Breast cancer may often present asymptomatically or 
may be detected by patients as they notice palpable breast lumps. The often-
asymptomatic nature of the disease necessitates early detection, as survival outcomes are very 
different depending on the cancer’s stage. More than 90% of breast cancers at the time of diagnosis 
are not metastatic [8], which tallies with the fact that 90% of breast cancer diagnoses have an overall 
survival rate of five years or more, despite the fact that only 15% of patients diagnosed with Stage IV 
are alive five years later. Thus, early detection and appropriate staging is crucial. 
 
This review outlines the molecular classification of breast cancer, along with how it is staged at the 
clinical level. After discussing existing treatment options, the review then proceeds to discuss novel 
emerging approaches for breast cancer, focussing on immunotherapy, and the role that multi-omics 
data can have in this. The review then closes with a “Future Perspectives” section, which details 
where it is anticipated this field could evolve in the coming years. 
 
Molecular Classification of Breast Cancer 
 
Breast cancer, overall, is commonly divided into four main molecular subtypes: luminal A, luminal B, 
triple negative, and human epidermal growth factor receptor 2 (HER2)-enriched. Luminal A is 
characterised by being oestrogen receptor (ER) and/or progesterone receptor (PR) positive, HER2 
negative, and possessing low expression levels of Ki67, a key protein driving breast cancer cell 
proliferation [9]. Comparatively, luminal B is characterised by possessing higher levels of Ki67 and 
may be HER2 positive or negative, whilst HER2-enriched breast cancers are ER and PR negative but 
HER2 positive [10]. Lastly, triple-negative breast cancer (TNBC) accounts for approximately 15% of all 
breast cancers [11] and is characterised by a lack of  ER and PR expression alongside a lack of (HER2 
amplification [11]. The lack of these key targets naturally leads to the poor prognosis of these 
patients, as targeted and endocrine therapies are not currently available for TNBC patients [11]. 
Understanding the molecular subtype of breast cancer is crucial as it has been shown to play a role 
in response to immunotherapies, for example different molecular subtypes may exhibit immune 






Breast Cancer Staging 
 
Breast cancer staging will primarily depend on the primary tumour site and size (T), the extent of 
regional lymph node involvement (N), and the existence of distant metastasis (M) [13-16]. The latest 
8th edition of the American Joint Committee on Cancer (AJCC) staging system also incorporates the 
use of other biomarkers such as oestrogen receptor (ER), progesterone receptor (PR) and human 
epidermal growth factor receptor 2 (HER2) for prognostic staging [17], which is also recommended 
in the National Institute for Health and Care Excellence (NICE) guidelines. NICE states that ER, PR and 
HER2 statuses of invasive breast cancers should be requested at the point of initial diagnosis 
confirmed by histological findings [18]. AJCC 8th edition also endorsed the use of multigene assays 
such as Oncotype Dx® and Mammaprint® in predicting prognosis for hormone receptor positive, 
HER2-negative breast cancer, while there is a lack of evidence to support the use of such tool in 
triple negative cancers and HER2-positive cancers [14]. Further work is, however, required to 
illustrate the additional value provided by Oncotype Dx as a recent analysis questioned the 
applicability of such multigene assay in a broader population [19].  
 
Current Standard Therapy for Breast Cancer 
 
Neoadjuvant therapies such as chemotherapy, radiotherapy and hormonal therapy aim to reduce 
tumour size and avoid mastectomies, and are provided prior to breast conserving surgeries (BCS) 
[20]. Neoadjuvant chemotherapy has been reported to be more effective than neoadjuvant 
hormonal therapy in ER+, HER2- cancers [21], though it was also acknowledged and highlighted the 
need to develop predictive biomarkers to guide neoadjuvant therapies [21]. Furthermore, it has also 
been advised that caution should be used in clinical practice surrounding the use of neoadjuvant 
therapies, as a recent meta-analysis reported that the use of neoadjuvant chemotherapy may have 
elevated risk of relapse than those who received adjuvant chemotherapy [22]. This was further 
supported by a March 2020 study which found that specific risk factors such as young age, TNBC, 
and node-positive tumours were associated with an elevated risk of locoregional recurrence after 
neoadjuvant chemotherapy [23]. There are further issues surrounding the use of neoadjuvant 
therapies, including (until recently) limited evidence in the literature comparing efficacies of 
different neoadjuvant therapies and a lack of standardisation for pathologic evaluation of post-
neoadjuvant breast cancer specimens in the routine clinical setting [24]. 
 
Following initial treatment with neoadjuvant chemotherapy, NICE recommends either mastectomy 
or BCS followed by radiotherapy for those suffering from locally advanced or inflammatory breast 
cancer [18]. It has been shown that patients who received BCS with radiotherapy had significantly 
higher overall survival and disease-specific survival than patients undergoing mastectomy, and that 
this was particularly true for patients aged over 50 with hormone receptor-positive tumours against 
patients under 50 with hormone-receptor negative tumours [25].  
 
The NICE guidelines also state that further surgeries should be offered after BCS in cases of invasive 
breast cancer or DCIS located at the radial margins. The primary goal in the surgical management of 
invasive breast cancer, in the absence of detectable lymph node involvement on ultrasound, is to 
accurately stage the axilla using sentinel lymph node biopsy (SLNB). Alternatively, axillary lymph 
node dissection (ALND) should be offered where there is evidence of metastatic lymphadenopathy 
on histopathology or sentinel lymph node macro-metastases following SLNB [18]. Radiotherapy 
should be offered to most patients with invasive breast cancer following BCS unless they have been 
assessed to have significantly lower absolute risk of relapse and will comply to a minimum 5 year 
course of adjuvant hormonal therapy [18]. Per NICE guidelines, chemotherapy is part of the adjuvant 
treatment of invasive breast cancer when justified by significant risk. This normally consists of a 
treatment regimen involving a taxane and an anthracycline [18]. In addition, depending on hormonal 
receptor and HER2 statuses, chemotherapy is also used in advanced breast cancer as a monotherapy 
or combined with immunotherapies such as monoclonal antibodies [26]. Figure 1 below summarises 






Figure 1: Overview of the management algorithm for early and locally advanced breast cancer. Information adapted from 
the NICE guidelines for early and locally advanced breast cancer [18]. 
 
Despite the above and overall good success rates for breast cancer remission, the treatments are of 
course associated with unpleasant side effects and not all patients are successfully treated. Thus, 
there has been an interest in developing alternative treatments that are more targeted, less toxic, 




Phototherapy (also known as light therapy) is the exposure of various forms of light for treating a 
number of conditions, which has been applied both clinically and experimentally in oncology. A key 
advantage of phototherapy, in general, is that it is non-invasive and can have high spatiotemporal 
precision [27]. The two main kinds of phototherapy to consider are photodynamic therapy (PDT), 
which involves a particular type of light along with a light-sensitive drug treatment (photosensitiser) 
or nanoparticle [28], and photothermal therapy (PTT) which, unlike photodynamic therapy, does not 
depend on oxygen for functionality [27]. PTT agents instead absorb light energy and convert it to 
heat to generate their anti-cancer effects [27, 29]. 
 
Liang and colleagues demonstrated the potential efficacy of PTT via an erythrocyte membrane-
coated black phosphorus quantum dot formulation (BPQD-RMN) which reduced basal-like breast 
tumour growth in-vivo [30]. Whilst there are a number of examples of the application of 
phototherapy to breast cancer research, of particular interest here is the potential to combine 
phototherapy with immunotherapy. As will be expanded upon further on in the review, 
programmed cell death 1 (PD-1) is a key immune checkpoint marker that is a frequent target for 
immunotherapy. The study by Liang and colleagues demonstrated that residual and metastatic 
tumour growth was delayed in vivo when BPQD-RMN-mediated phototherapy was combined with 
an antibody against PD-1, as a result of reduced CD8+ T cell exhaustion [30, 31]. Thus, combining 
phototherapy with other promising approaches such as immunotherapy could offer further 
therapeutic benefits.  
 
Introduction to Immunotherapy 
 
Immunotherapy is a constantly evolving field aiming to encourage the immune system to target 
tumour cells more effectively while intending to bypass the side effects of existing treatment options 
[32]. There are various treatment opportunities branching out from immunotherapy. Some 
examples of these include immunotherapeutic vaccinations, immune checkpoint blockade, oncolytic 
virotherapy and antitumor monoclonal antibodies [33]. Cancer immunotherapy can be categorised 
into active and passive immunity. Immunotherapeutic injection is one of the most common 
examples of active immunotherapy. This results in stimulation of a prolonged immune response and 
memory. In contrast is passive immunotherapy which 
produces short-lived responses requiring regular 
administration of the treatment, due to not activating the immune system in a systematic manner in 
situ and relying on isolated effectors activated in vitro [34, 35]. 
 
One of the challenges associated with immunotherapy is resistance to treatment, more 
specifically acquired resistance, in which immunotherapy 
initially demonstrated success initially with the cancer, but it relapsed after some time had passed 
[36]. Immunogenic in nature, T-lymphocytes constitute the majority (70-80%) of immune cells in 
breast cancer tissue. B-lymphocytes, macrophages, antigen presenting cells and natural killer (NK) 
cells account for the remaining immune cells in breast cancer tissue [37]. Tumours expressing human 
epidermal growth factor receptor 2 (HER2), along with triple-negative breast cancer 
(TNBC), can be viewed as the most immunogenic subtypes of breast cancer. Various immunotherapy 
strategies are currently being investigated for treatment of breast cancer [38]. 
 
Immunotherapeutic vaccinations for breast cancer 
 
Vaccines can be separated into two categories: prophylactic (preferred for cancers with an infectious 
aetiology) or therapeutic (aim to treat an existing disease by utilising a patient’s immune system) 
[33, 39]. In general, vaccines developed for cancer aim to initiate type I CD 4+ or 8+ T cell responses 
[33, 39]. In general, vaccines developed for cancer aim to initiate type I CD 4+ or 8+ T cell responses 
[33, 39]. In general, vaccines 
developed for cancer aim to initiate type I CD 4+ or 8+ T cell responses against tumour associated 
antigens (TAAs) [40]. Breast cancer has associations with various TAAs such as HER2 and Mucin 1 
(MUC1). Approximately 20% of breast cancer patients express HER2 and overexpression of mucin 
especially MUC1, MUC3 and MUC4 is commonly observed in breast cancer. Targeting the previously 
mentioned sites have shown clinical benefit [37, 41, 42]. Figure 2 below summarizes the various type 








As clarified earlier, HER2 (ERBB2) expression is associated with an increased mortality and 
 




Belonging to the mucoprotein family, MUC1 is a high molecular weight glycoprotein which is 
increasingly expressed among various carcinomas such as ovarian and breast cancer. Expression of 
certain tumour associated carbohydrate residues including sialyl-Tn (STn) antigens (+ Thomsen-
Freidenreich) are a consequence of aberrant glycosylation [37, 40]. Poor prognosis of breast cancer 
can be linked to high levels of STn [51]. A Phase III trial involved the administration of STn vaccine 
conjugated to keyhole-limpet Hemocyanin (KLH) (also referred to as Theratope). This study recruited 
1028 women with MBC. Despite it being well tolerated, Theratope administration had no effect on 
overall survival (OS) or time to progression duration. However, simultaneous administration of 
Theratope and endocrine therapy resulted in a statistically significant OS difference [51]. Another 
study administered a poxviral vaccines, PANVAC, which contained transgenes for MUC-1, CEA and 3 
T-cell co-stimulatory molecules. There were no grade 3 or 4 toxicities observed with PANVAC 
administration. This study benefited patients with limited tumour burden or those with minimal 
history of chemotherapy [37, 52]. NCT03524261 is an upcoming phase II clinical trial involving the 






Lapuleucel-T (APC8024) is formulated from a combination of peripheral mononuclear cells 
incorporating antigen-presenting cells with BA7072 (recombinant fusion protein) [37, 53]. A phase I 
study was conducted to assess the benefit of lapuleucel-T in 19 patients with MBC overexpressing 
HER2. This therapy was well-tolerated with pyrexia (74%) and rigors (58%) as the most common 
adverse effects. Lymphocyte proliferation and interferon gamma enzyme-linked immunospot assay 
measured a noteworthy immune response following administration with above treatment. 
Furthermore, 3 patients reported stable disease lasting ≥ 1 year [53].  
 
Dendritic cell (DC)-based 
 
A study administered DCs pulsed with either HER2/MUC-1 in patients with ovarian (3/10) and breast 
cancer (7/10). DC vaccine was well tolerated, and 5/10 patients peripheral blood sample contained 
cytotoxic T-lymphocytes specific to a peptide. This study obtained results that showed potential for 
DCs pulsed with a single antigen in treatment of ovarian and breast cancer [54]. One clinical trial 
involved the administration of dendritic cells vaccinations pulsed with HER2 were stimulated in vitro 
with interferon gamma (IFN and bacterial lipopolysaccharide [55]. This process allowed that the 
dendritic cells to exude increased levels of interleukin-12p70. Increased levels of sensitisation 
towards peptides including IFN γ secreting CD4 and 8 were observed. 7/11 patient’s surgical tumour 
samples revealed lower levels of HER2 expression [55]. This trial displayed potential in treating early 
stage breast cancer. However further trials are required to draw conclusions about the safety and 
efficacy of DC based vaccinations for breast cancer. NCT04105582 is an on-going phase I trial aiming 
to vaccinate TNBC patients with autologous DCs. NCT03384914 is another on-going clinical trial 
intending to evaluate the safety and efficacy of two vaccines (DC1 and WOKVAC) in both, female and 
male patients with breast cancer.  
 
In summary, vaccines developed for prevention or treatment of breast cancer have not been 
approved yet. Modifications of various factors such as route of delivery, timing of vaccine 
administration, patient selection and optimal combination of therapies could enhance the 
effectiveness of breast cancer vaccines [56]. Additionally, the use of high-throughput methodologies, 
as discussed further on in the manuscript, can aid in the identification of neoantigens that may 
facilitate vaccine development, with the added benefit of neoantigens being tumour-specific 
antigens (TSAs) rather than tumour associated. This is of key importance, as the specific nature of 
the TSA results in a negligible risk of triggering severe adverse-related events due to non-specificity, 
in contrast to TAAs [57]. 
 
Immune checkpoint blockade 
 
Located on T-cell surfaces, immune checkpoint receptors communicate either positive or negative 
signals to T cells. Cytotoxic T-lymphocyte antigen-4 (CTLA-4), Programmed cell death 1 (PD-1) and 
lymphocyte activation gene 3 (LAG-3) are some examples inhibiting T cell immune responses. 
Conversely, OX40 is a receptor that stimulates T-cell activity via positive signals [38]. The 
development of inhibitory antibodies aimed at immune checkpoints has shown promise in the 
treatment of various cancers such as breast cancer, bladder cancer and melanoma [37].  
 
CTLA-4 Inhibitors  
 
Tremelimumab and ipilimumab are examples of anti-CTLA-4 monoclonal antibodies that are being 
tested for breast cancer treatment [24]. Apart from stimulating T-cell activation, tremelimumab aims 
to prevent CTLA4 binding to CD80 and CD86. A phase I study recruited 26 patients with ER-positive 
advanced breast cancer and administered tremelimumab plus exemestane to establish their efficacy 
in breast cancer treatment and judge tumour or immune responses. This combination was tolerated 
in patients with the majority experiencing grade I or II toxicities. Diarrhoea (46%) and pruritus (42%) 
were two of the most common adverse effects. This trial revealed stable disease in 11 patients (42%) 
for ≥12 weeks. Additionally, increased levels of inducible costimulator plus T cells were observed 
which most likely resulted in immune activation secondary to CTLA-4 blockade [58]. In a pilot study, 
ipilimumab with or without cryoablation was administered to 19 patients with early stage breast 
cancer. Cryoablation with ipilimumab revealed a limited increase in the ratio of CD8+Ki67 tumour T 
cells to T-regulatory cells. Treatment with ipilimumab alone resulted in activated T-cells in the 
bloodstream [59]. Table 1 summarises ongoing clinical trials for breast cancer treatment involving 
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A phase I/II trial demonstrated the application of chemoimmunotherapy in 30 patients with MBC. A 
soluble kind of LAG-3, IMP321 (LAG-31g) was administered in combination with paclitaxel to these 
patients [38, 60]. IMP321 helps to prolong an initial immune response that is initiated by 
chemotherapy application. The combined regimen was well tolerated, and clinical benefit was seen 
at 6 months for 90% of patients. An increase in the both, quantity and activation of antigen 
presenting cells plus an increase in the amount of NK and CD8 T cells was attributed to the 
application of IMP321 [60]. Further phase II/III trials are necessary to confirm the advantage of 
chemoimmunotherapy application in breast cancer patients. NCT02614833 is an active phase II 
clinical trial assessing IMP321 with standard chemotherapy paclitaxel in patients with hormone 
receptor-positive breast cancer. 
 
PD-1 & PD-L1 Inhibitors 
 
Expressed on activated NK cells, monocytes, dendritic cells, T cells, B cells and myeloid cells, PD-1 is 
an inhibitory immune checkpoint receptor. PD-L1 (CD274 or B7-H1) and PD-L2 (CD273 or B7-DC) are 
the main ligand partners for PD-1. Negative regulation of T-cells is a consequence of PD-1/PD-L1 
expression.  Approximately 20-30% of breast cancer patients, especially those with TNBC, exhibit PD-
L1 [37, 38, 61]. A phase Ib nonrandomised trial was conducted to assess the application of 
pembrolizumab (MK-3475) in patients with TNBC. Arthralgia (18.8%), fatigue (18.8%), myalgia 
(18.8%) and nausea (15.6%) were the most common adverse effects observed. 15.6% of patients 
enrolled experienced one or more grade 3-5 adverse event. Pembrolizumab administration exhibited 
an overall response rate (ORR) of 18.5% comprising of one complete response. However, the 
treatment(s) patients received prior to the trial and high-LDL levels of patient must be considered 
when reviewing the ORR [61]. NCT02447003 is an on-going phase II trial to assess pembrolizumab 
monotherapy in patients with metastatic TNBC. NCT02054806 is another on-going phase I clinical 
trial assessing the application of pembrolizumab among patients with incurable advanced biomarker 
positive solid tumours. A humanized monoclonal antibody, Atezolizumab (MPDL3280A) functions to 
rebuild tumour associated T-cell immunity through inhibition of PD-L1 to PD-1. Atezolizumab plus 
nab-paclitaxel was administered to 11 patients with metastatic TNBC. This combination was well-
tolerated, and its promising results encouraged an on-going phase III trial of atezolizumab with nab-
paclitaxel among previously untreated patients with metastatic TNBC (ClinicalTrials.gov identifier: 
NCT02425891) [62]. NCT01633970 is another on-going clinical trial involving atezolizumab 
administration with bevacizumab and/or chemotherapy among patients with locally advanced or 
metastatic solid tumours. Durvalumab (anti-PD-L1) and nivolumab (anti-PD-1) are other inhibitors 
being tested for breast cancer treatment. 
 
Although immunotherapy holds much promise, clinical trial results should always be interpreted 
with a healthy dose of caution. Many clinical trials will utilise progression-free survival (PFS) as an 
endpoint on the trial, sometimes alongside but sometimes without overall survival (OS). In any case, 
results reported with surrogate endpoints such as PFS should be interpreted cautiously, as research 
has shown that immunotherapeutic treatment effect sizes with PFS were 17% greater, on average, 
than with OS [63]. In the case of breast cancer, only little to moderate correlation (surrogacy) 
between PFS and OS has been shown, which is also true for other surrogate endpoints such as 
disease control and time to progression [64, 65]. In the case of immune-checkpoint blockade, the 
majority of the focus is on CTLA-4 and PD-1/PDL-1, though it has rightly been argued that there are 
other immune checkpoints that can be focussed upon , and indeed high-throughput ‘omics’ 
methodologies can help with this [66]. 
 
‘Omics’ Data and Computational Biology 
 
Improved technologies and research methodologies have allowed for the examination of biological 
data in an integrated, cohesive, and holistic manner, by looking at a much wider facet of the biology 
than traditional laboratory experimentation would have allowed. In particular, the use of ‘omics’ 
technologies (genomics, proteomics, metabolomics, etc) allows for exceptionally large amounts of 
data to be generated and analysed. Through the use of computational biology it is possible to 
integrate this data and analyse it, and also utilise it for other purposes. Systems biology is a field that 
aims to accurately model biological data, particularly for entire systems, and this can be done for key 
cancer proteins such as TP53 (mutated in over half of human cancers) [67]. This kind of modelling 
may also be performed for nuclear hormone receptors such as the oestrogen receptor, which is 
evidently important for breast cancer therapy. The proof of principle for this came from the 2017 
paper which modelled the glucocorticoid hormone receptor for leukaemia [68]. 
 
Both this TP53 model and the GR model were Boolean in silico simulations of the protein interaction 
networks surrounding each protein. These models were capable of generating predictions (following 
in silico mutations) as to how the network would operate following an in vivo loss-of-function 
mutation, and model validation by literature mining and experimental data demonstrated good 
prediction rates for each, above that of a random model. In particular, these models were capable of 
being integrated with high-throughput experimental data, and were each validated by microarray 
data from both cancer cell lines in the laboratory harbouring the mutations simulated or from cancer 
patients [67, 68]. In the case of the GR model, preliminary model validation demonstrated potential 
correlation of the model’s prediction of the disease’s severity with the survival length of patients, 
though the authors noted it should be interpreted cautiously and preliminarily [68]. 
 
Analysis of these types of models were taken further forward by integrating mesothelioma patient 
RNA-seq data with the TP53 model [69]. Data from the study by Bueno and colleagues [70] which 
looked at transcriptomes and exomes, was utilised for this. The RNA-seq data from 71 mesothelioma 
patients was collectively analysed, and patients were subgrouped based on factors such as 
treatment and mutation status. By combining this data with the model analysis, the authors were 
able to identify particular up- and down-regulated genes that represented therapeutic targets in 
different subpopulations. These targets were then verified through in vitro laboratory 
methodologies. Thus, the development of these models represents a way to utilise the high-
throughput data that exists and may be a step towards personalised therapy. 
 
It is certainly possible that this kind of model could be built for genes/proteins key to breast cancer
, and superimposition of cell-line or patient-based omics data to such a 
model would no doubt provide similar therapeutic insights to breast cancer signalling, much as the 
GR model did for leukaemia and the re-analysis of the TP53 model did for mesothelioma [67-69]. 
Should such models be built for breast cancer
 it would no doubt provide novel insights into breast cancer 
signalling following the use of in silico mutations and the use of omics-type data to 
validate predictions. 
 
Application of Multi-Omics Data to Breast Cancer 
 
Further to the above-described application of omics-type data to computational models, it is also 
Further to the above-described application of omics-type data to computational models, it is also 
Further to the above-described application of omics-type data to computational models, it is also 
Further to the above-described application of omics-type 
data to computational models, it is also important to consider the benefits of looking at different 
types of omics data collectively rather than individually, such as analysing transcriptome, 
epigenome and proteome data concurrently to generate an overall conclusion. The use of multi-
omics data in oncology from a general perspective has been comprehensively reviewed by 
Chakraborty and colleagues [71]. In principle, whilst there is increasing complexity from genome 
through to proteome and single-type omics data can provide highly useful information (for instance 
mutation identification), the complexity of cancer at many levels requires a deeper level of 
investigation than single-omics data can provide [71]. A simple example would be that mutations 
identified in whole-genome DNA sequencing may not have any importance due to lack of 
expression, which is something a proteomics screen could identify – or alternatively an epigenome 
screen could identify if a wild-type gene is instead inactive through epigenetic mechanisms. Thus, 
integration of multiple types of omics data allows for a wider holistic view of cancer. An example of 
the importance of multi-omics data is through a
 
In the case of breast cancer, whilst there have been several multi-omics 
studies, there are notably fewer that are specifically related to immunotherapy. Thus, a number of 
multi-omics approaches are discussed herein in the wider context, rather than directing focus 
specifically to its application to immunotherapy, though there are studies that relate to specific 
elements such as the tumour microenvironment and neoantigen prediction, the latter of which is of 
course important for therapeutic vaccine development. 
 
 
A second 2016 study generated proteomic and phosphoproteomic data to identify the 
functional consequence of somatic mutations identified at the genome level, highlighting potential 
therapeutic targets and narrowing candidate nominations for driver genes [73]. The study by 
Mertins and colleagues also highlighted the importance of a multi-omics approach through their 
identification of a G-protein-coupled receptor cluster in the phosphoproteome data that was not 
easily identifiable at the mRNA level [73]. In this study, genomic and transcriptomic variants were 
identified at the peptide level through searching high-resolution accurate-mass tandem mass 
spectrometry (MS/MS) data that were not matched to RefSeq against a patient-specific sequence 
database. Notably, although RNA-seq detected them only as single transcript reads, this MS/MS 
approach identified a number of splice isoforms, along with several single amino acid variants, splice 
junctions, and frameshifts [73]. Ultimately, however, the number of genomic and transcriptomic 
variants confirmed by MS/MS as peptides was low. The study by Mertins and colleagues provided 
further evidence of the benefit of integrated analysis, as their study identified that protein kinases 
such as CDK12, often encompassed in the ERBB2 (HER2) amplicon, were upregulated at the RNA, 
protein, and phosphoprotein level and showed similar gene-amplification-driven proteogenomic 
patterns to HER2 [73]. Given the continuing search for druggable targets such as tyrosine kinases, 
the identification of CDK12 as highly active in the majority of HER2-positive tumours is of interest 
[73]
The importance of metabolism in cancer, most famously highlighted via the Warburg effect (usage of 
aerobic glycolysis), lends itself to multi-omics investigation. Terunuma and colleagues undertook a 
metabolomics approach and identified 2-hydroxyglutarate (2-HG) accumulation in a subset of 
tumour types which was also linked to aberrant MYC activation [74]. The study also found that 2-HG 
could promote cellular proliferation and inhibit apoptosis. Auslander and colleagues conducted an 
integrated analysis of metabolome and transcriptome data to develop a model that predicted 
metabolite levels based on the expression level of the enzymes catalysing them [75]. This prediction 
method was then analysed against a large dataset of breast cancer patients to estimate the 
importance of the metabolite concentration for patient survival. The depletion of key cancer-related 
metabolites such as glucose and acetate appeared to be significantly correlated with improved 
patient survival [75]. The authors also argued that the limited possibilities of metabolomic targeting 
leads to the possibility of their prediction pipeline having utility in deciphering the role of different 
metabolites in cancer progression and prediction of biomarkers for early detection and prognosis. 
This thus demonstrates additional usage of multi-omics approaches.  
 
There have been several studies published in 2020 that relate to multi-omics data. Huang and 
colleagues, in May 2020, released an article detailing an integrated genome-wide DNA methylation 
analysis, protein profile analysis, and metabolme analysis on MCF-7 breast cancer cells treated with 
estradiol (E2, an oestrogen) and/or sulforaphane (SFN) (a chemopreventive phytochemical) [76]. 
Interestingly, this study found that combined E2 and SFN treatment showed a similar DNA 
methylation profile to the control cells, indicating that the chemoprotective effects of SFN may arise 
through reversing the effects of E2 [76]. Among other results, when the DNA methylation, protein 
and metabolite analyses were integrated by annotating the methylated genes and proteins with 
Gene Ontology (GO) terms and metabolic pathway enrichment identified by Reactome. By using 
KEGG to map metabolites to the corresponding pathways, the authors were able to locate the 
common pathway of genes, proteins and metabolites [76]. This process also identified differentially 
methylated genes and differentially expressed proteins, and the approach identified that the 
reversal effects of SFN were associated with glutathione metabolism and purine metabolism. 
Ultimately the integrated approach provided a ‘blueprint’ of the relationship of the biological 
molecules at different stages, facilitating the mechanistic understanding of chemopreventive 
medicines [76], and is a further example of the use of multiple data in concurrence demonstrating 
deeper insight. 
 
A fundamental driver anti-cancer therapy is of course an understanding of apoptotic pathways and 
the key players therein. Again in May 2020, Wang and colleagues sought to identify the spatial 
pattern of BCL2 gene family members within the context of chromatin using correlations between 
gene expression, gene alteration, and chromatin accessibility, all related to clinical outcomes in 
gynaecologic and breast cancer [77]. The study focussed on integrating multi-omics data available 
from a number of sources cBioPortal, Gene Expression Profiling Interactive Analysis (GEPIA), and 
assay of transposase‐accessible chromatin with sequencing datasets available from the UCSC Xena 
browser [77]. Focussing on gynaecological tumours, the authors found that differential BCL2 family 
member expression was paired with widespread chromatin accessibility changes, in addition to the 
authors noting a relationship between ‘gene expression, gene amplification, enhancer signatures, 
DNA methylation and overall patient survival’ [77]. The study identified clinical correlations with 
genes such as BAD, BIK and BAK1 via prognostic analysis. Whilst this study focussed on gynaecologic 
cancers, such an approach could certainly be adopted for different types of breast cancer to 
generate equivalent results.   
 
Karim and colleagues, in January 2020, undertook a multi-omics pan-cancer approach to analyse the 
importance of bone morphogenic protein 5 (BMP5), due to conflicting literature [78]. To do this, a 
number of resources were utilised including (but not limited to) ONCOMINE (mRNA analysis) [79], 
Gene Expression across Normal and Tumor tissue (GENT, http://gent2.appex.kr/gent2/) [80], 
UALCAN (used for the expression pattern of BMP5 mRNA, but can also analyse promoter 
methylation, correlation, and prognosis) [81], PrognoScan (determination of potential tumor 
biomarkers and therapeutic targets) [82] and cBioPortal [83, 84], which contains a range of data 
including mRNA level and DNA methylation data. The integration of the numerous sets of data 
allowed the authors to come to a more robust conclusion, identifying via a prognostic analysis that 
there was a negative association of BMP5 downregulation with four types of cancer, including breast 
[78]. Whilst it is possible to use multi-omics approaches to look at the ‘big picture’ or at molecular 
signatures, for example, such data may also be useful to conduct a sort of meta-analysis of a number 
of different datasets to come to key conclusions surrounding one gene in different contexts. 
 
Cui and colleagues recently undertook a multi-omics approach investigating expression data of long 
non-coding RNAs (lncRNAs), microRNAs, mRNA, as well as methylation levels and somatic mutations, 
along with patient survival data following drug treatment [85]. The aim was to evaluate the drug 
responses of patients from a multi-omics perspective, to gain a wider understanding. The study 
identified drug response-related lncRNAs (DRIncs) through their integrated analysis, which is of 
potential therapeutic benefit through increased understanding of the molecular mechanisms 
underlying drug response [85]. This study represents a strong example of applying multi-omics data 
to understand molecular response at numerous levels. 
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In relation to the immune system, multi-omics data has also been utilised to investigate the tumour 
microenvironment (TME), which consists not only of cancer cells but also other cell types such as 
tumour-infiltrating immune cells, secreted factors such as cytokines and non-cellular elements of the 
extracellular matrix (ECM) [86]. The TME is known to be important for breast cancer development 
and progression, and also offers the opportunity for therapeutic targeting [87]. From an 
immunotherapy perspective, the fact that most patients do not respond to immune checkpoint 
blockade, despite its potential and inclusion on patient regimens, highlights the need to look at the 
TME in further detail for its involvement in this [86]. Multi-omics profiling of the TME has been 
reviewed in more detail by Finotello and Eduati [86]. 
 
Xiao and colleagues, on behalf of the AME Breast Cancer Collaborative Group, recently conducted a 
large study involving extensive immunogenomic analysis to identify the heterogeneity and 
prognostic significance of the tumour microenvironment in triple-negative breast cancer [88], on the 
back of data indicating lack of success for immunotherapies for TNBC despite its higher 
immunogenicity than other breast cancers [88]. 386 TNBC samples were analysed involving a range 
of data sources including OncoScan microarray copy-number data (n = 335), tumour RNA-seq data (n 
= 245; paired normal tissues: n = 90), hematoxylin and eosin (H & E) sections data (n = 300), whole-
exome sequencing data (n = 268), tissue microarray data (n = 181) and HTA 2.0 microarray data (n = 
141) [88]. 
 
From the above, the TNBC microenvironments were classified into three heterogenous clusters: 
“cluster 1, the “immune-desert” cluster, with low microenvironment cell infiltration; cluster 2, the 
“innate immune-inactivated” cluster, with resting innate immune cells and nonimmune stromal cells 
infiltration; and cluster 3, the “immune-inflamed” cluster, with abundant adaptive and innate 
immune cells infiltration” [88]. It was found by Xiao and colleagues that the clusters had significant 
prognostic potential, with cluster 1 being unable to attract immune cells, cluster 2 demonstrating 
features that possibly contribute to immune evasion, whilst cluster 3 featured high expression of 
immune checkpoint molecules [88]. Such analysis may pave the way forward for patient 
stratification for immunotherapy trials, by specifically selecting patients exhibiting a similar profile to 
“cluster 3”. 
 
Similar to the above is the study by McGrail and colleagues [89], which aimed to investigate the 
causes behind immune invasion in recurrent copy number alteration-driven cancers such as breast 
cancer, as the levels of cytotoxic T-lymphocytes (CTLs) does not correlate with neoantigen 
expression in these cancer types. McGrail and colleagues utilised an integrated multi-omics 
framework inclusive of proteomic data, gene expression data, genetic mutation phosphor-/total-
proteomics along with interactome networks. This study unveiled that CTL levels in breast cancer 
correlate with ATM expression, and that ATM expression was linked to elevated cytokine secretion, 
in turn promoting CTL infiltration [89]. The identification of driving factors of immune infiltration is 
key to improving existing immunotherapeutics, and thus this study highlights another example of 
how multi-omics data may be beneficial for pushing breast cancer therapies forward. 
 
Multi-omics profiling has also been employed to investigate differences in molecular signatures 
between different patient cohorts [90]. Kan and colleagues compared whole exomes and 
transcriptomes of a Korean breast cancer patient cohort (primarily pre-menopausal) to a primarily 
Caucasian and post-menopausal breast cancer patient cohort available from the TCGA [90]. 
Curiously, it was found that the Korean cohort had a larger proportion of HER2-enriched and luminal 
B molecular subtypes, and a lower proportion of luminal A with lower ER expression [90]. The same 
patient cohort also demonstrated a higher level of mutation in BRCA1, BRCA2, and TP53, and were 
also found, overall, to have higher levels of tumour-infiltrating lymphocytes (TILs) and higher 
expression of PD-L1 [90]. This study therefore clearly demonstrates the importance of identifying 
molecular signatures associated with particular molecular subtypes of cancer and with particular 
patient cohorts, as knowledge of this may further promote stratified patient treatment. It also is 
concurrent with the knowledge that TIL density correlates with PD-L1 expression in breast cancer 
[91]. 
 
A key aspect of the response to immunotherapy is reportedly the tumour mutational burden (TMB). 
The role of TMB in relation to breast cancer has been comprehensively analysed in March 2020 by 
Barroso-Sousa and colleagues using sequencing data of 3969 patients [92]. In principle, high tumour 
burden was found in only 5% of breast cancer cases and was more common in metastatic tumours; 
however, it was proposed that those patients that exhibit hypermutation were more likely to benefit 
from immune checkpoint blockade in the form of PD-1 inhibition [92]. Hormone receptor-negative 
and HER2-negative tumours were found to have a higher level of tumour mutational burden than 
HER2-enriched tumours, which in turn had higher mutational burden than hormone receptor-
positive and HER2-negative tumours [92]. 
 
In the same study, APOBEC activity and mismatch repair deficiency (MMRd) were the most common 
mutational processes in the hypermutated tumours at 59.2% and 36.4% respectively[92]. APOBEC 
represents a crucial area of study, as APOBEC has been shown to generate mutational signatures in 
breast cancer, and is associated with higher tumour mutational burden [93]. Additionally, APOBEC 
has been fundamentally identified as a key enzymatic driver of mutation in breast cancer, promoting 
C-T mutations [94]. Chen and colleagues conducted an integrated genomic and association analysis 
using data from ten cancer types from TCGA, investigating APOBEC3A and APOBEC3B, APOBEC-
mutational signature, germline APOBEC3A/B deletions, neoantigen loads, and TILs [93]. A key finding 
from the study was that germline APOBEC3A/B deletion resulted in elevated APOBEC mutational 





Neoantigen expression is considered an important determinant in the response to immunotherapy, 
and the use of multi-omics data to consider the wider TME and its relationship to tumour cells can 
help to uncover relationships between tumour cells and immune cells. For instance, RNA-seq data 
has been utilised in-conjunction with whole-genome or exome data to predict patient-specific 
neoantigens [86]. In this context, the use of the word neoantigen means a peptide resulting from a 
somatic mutation present in the cancer cells and hence not expressed on healthy cells, leading to 
targeted therapy. As is clear from the above section, high tumour mutational burden is associated 
with elevated levels of neoantigens [92] It follows logically that high levels of neoantigens correlate 
with improved response to immunotherapies, and this does indeed seem to be the case for immune 
checkpoint blockade [95-97], though in the case of breast cancer immune infiltration does not 
correlate with neoantigen levels [89]. Matching tumour omics data with equivalent data from 
normal cells can allow for the identification of neo-antigens on a patient-by-patient basis [95]. These 
identified (or predicted) neoantigens then need to be ranked according to their likelihood to induce 
a T-cell response. 
 
Despite the potential of this approach, as of August 2019 there was no formalised consensus 
approach and few best practice guidelines [95] for this procedure. However, generally speaking, 
after the analysis of matched DNA sequence data to identify somatic mutations, human leukocyte 
antigen (HLA) haplotyping should be performed to determine the patient’s HLA alleles and their 
corresponding MHC class. RNA-seq data can then be used to calculate the expression levels of 
neoantigens before ranking. There are many bioinformatics tools utilised to perform these 
procedures, reviewed by Richters and colleagues [95]. A key benefit of neoantigen prediction is the 
possibility of deriving novel immunotherapy vaccinations, the most frequent of which are synthetic 
long peptide (SLP), tumour cell, nucleic acid, and dendritic cell (DC)-based vaccines [98] The promise 
of this approach of neoantigen identification/prediction is evident due to there being several clinical 
trials currently investigating neoantigens, with examples summarised below in Table 2: 
 
Table 2: Clinical trials involving neoantigens in breast cancer that are either ongoing, recruiting, or not yet recruiting. All 
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weeks for up 
to 6 doses. 
 
 
Accessing Multi-Omics Data 
 
 
It is evident that there are a significant number of studies related to multi-omics techniques applied 
to breast cancer, though admittedly significantly fewer specifically related to immunotherapy. Such 
studies drive the need for a centralised resource to collate this data and provide it in an accessible 
format. DriverDBv3 is a multi-omics database for cancer driver gene research that can help to 
identify driving genes [99], whilst the Multi-Omics Breast Cancer Database (MOBCdb) is a breast 
cancer-specific database that integrates genomic, transcriptomic, and epigenomic data, along with 
clinical and drug response data of different breast cancer subtypes [100]. MOBCdb allows for the 
retrieval of gene expression, micro RNA (miRNA) expression, epigenetic information such as DNA 
methylation and drug response data and also provides an interface for simultaneous visualisation of 
multi-sample multi-omics data. Ultimately the database provides an accessible resource which 
enables researchers to identify novel potential biomarkers for targeted therapy and precision 
medicine [100]. A third database is ClinOmicsTrailbc, which is a visual analytic tool for breast cancer 
that assesses existing drugs and potentially repurposed drugs, along with immunotherapeutic 
approaches [101]. This tool integrates clinical markers and (epi-)genomics and transcriptomic data to 
evaluate driver mutations, tumour mutational burden, and activity patterns of key cancer pathways, 
among other features [101]. 
 
In addition to these databases, there are a number of bioinformatic tools and platforms that 
facilitate the analysis of multi-omics data, such as bioCancer 
(https://bioconductor.org/packages/release/bioc/html/bioCancer.html), a package for 
Bioconductor, that visualises and interactively analyse multi-omics data. Different integration tools 
and methods for multi-omics data has recently been comprehensively reviewed by Subramanian and 
colleagues [102]. In general, the presence of these databases and analytical tools and methods 





It is evident that the use of omics-type data, particularly integrated multi-omics analyses, has 
significant potential both from a patient stratification perspective and a therapeutic targeting 
perspective. The advances in bioinformatic and computational biology tools allow for more 
comprehensive and holistic analyses to be performed than was previously possible. Although these 
technologies allow for the identification of potentially novel therapies, when conducting clinical 
trials, it is important to ensure that appropriate, robust endpoints are used, and that studies or 
conclusions based on surrogate endpoints are interpreted with the appropriate caution. As time 
goes forward, it is anticipated that multi-omics approaches will become the standard, and integrate 
the ‘classical’ genomic, transcriptomic, and proteomic analyses with more specific areas which are 
showing increased importance such as miRNA screening, metabolomics, and omics-analysis of the 
role of dysbiosis in breast cancer. Systems biology, the subfield of computational biology which aims 
to construct accurate models of entire systems, is likely to play a significant role going forward for 
oncology as technologies improve, as accurate in silico simulation of important cancer pathways and 
superimposition of multi-omics-type data to these could be a bridge towards personalised therapy. 
It is anticipated that new and evolving therapies, including phototherapy, could be combined with 
the wealth of this ‘omics-type’ data to promote targeted and personalised applications, for instance 





Basics of Breast Cancer: 
 
• Breast cancer remains one of the most common cancer types, and can be classified into four 
main molecular subtypes: luminal A, luminal B, HER2-enriched and triple-negative (ER-, PR-, 
HER2-). 
• Breast cancer is staged at a clinical level according to the TNM classification of tumours 
which considers the tumour size, lymph node involvement, and metastases 
• Breast cancer may currently be treated through radiotherapy, chemotherapy, and surgery. 
Although the current standard of care shows good  therapeutic success, there is still unmet 
need for some patients, particularly for triple-negative breast cancer, and there is a push for 




• Immunotherapy is an approach that aims to utilise patients’ immune systems to treat 
cancer, as oppose to the use of cytotoxic drugs or invasive surgery. 
• There are numerous types of immunotherapy, such as immunotherapeutic vaccination and 
immune checkpoint blockade. 
• Immune checkpoint blockade works on the principle that blocking the immune-
downregulatory signals will help the immune system to remain active and target cancer 
cells, with common targets being CTLA-4 and PD-1/PD-L1 
• Immunotherapy, particularly immune checkpoint blockade, holds significant potential and 
may allow cancer to become a more managed disease, as opposed to current treatments 
which generally do not target cancer specifically. However, there are improvements to be 
made due to the relatively low success rate, side-effects and toxicity of immunotherapies 
 
Omics Data and Computational Biology 
 
• The use of high-throughput data allows for tumour cell biology to be comprehensively 
analysed, and this can be performed at the mRNA (transcriptomics), protein (proteomics) or 
epigenome (epigenomics) level, among others 
• In order to analyse such data effectively, it is essential to utilise bioinformatics and 
computational biology 
• Computational biology also allows for the modelling of key cancer networks, but a step 
forward from this is multi-omics data analysis which can integrate information from the 
genome, to the transcriptome, to the proteome and beyond. 
• Such integrated multi-omics analysis provides a deeper and more holistic view of cancer 





• There are many uses of multi-omics data, such as comparing different patient cohorts to 
identify molecular signatures and understanding tumour mutational burden 
• A popular approach in multi-omics data, which is linked to immunotherapy and has current 
clinical trials related to it, is neoantigen identification. Such approaches and the promise of 
training the immune system to target cancer, offer significant therapeutic promise 
• To facilitate research into multi-omics data, there are a number of databases and resources 
such as MOBCdb and bioCancer that aid in the visualisation and analysis of the integrated 
data 
• The use of multi-omics data may allow us to develop a deeper understanding of cancer cell 
biology between different patient cohorts, thus allowing for patient stratification. However, 
any clinical trial, particularly those investigating immunotherapy, should utilise robust 
endpoints where possible, due to the limited surrogacy of intermediate endpoints such as 
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